# AI-081

Source: https://onco.cc/drugs/ai-081/  
OnCo record `ai-081` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AI-081 is an experimental bispecific antibody from OncoC4 in phase 2 trials, aimed at PD-1 and VEGF / VEGFR.

## Summary

AI-081 is a bispecific antibody developed by OncoC4. Its targets are PD-1 and VEGF / VEGFR (the sponsor names PD-1/VEGF). The sponsor states: dual checkpoint and angiogenesis inhibition. ClinicalTrials.gov describes the intervention as: AI-081 is a humanized monoclonal antibody targeting PD-1 and VEGF. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06635785, plans to enrol 387 participants with primary completion expected 2027-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: Bispecific anti-PD-1/VEGF
- Tags: pipeline; ctgov-ingest
- Modality: bispecific antibody
- Mechanism: dual checkpoint and angiogenesis inhibition.

## Sources

- ClinicalTrials.gov: trials of AI-081: https://clinicaltrials.gov/search?intr=AI-081
- Sponsor page: https://www.oncoc4.com/en/pipeline/pipeline/

## Connected records

- targets: [PD-1](https://onco.cc/targets/pd1/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- companies: [OncoC4](https://onco.cc/companies/oncoc4/)
- trials: [Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors](https://onco.cc/trials/nct06635785/)

---
JSON: https://onco.cc/api/v1/entities/ai-081.json